Drug Search Results
More Filters [+]

Pateclizumab

Alternative Names: pateclizumab, mlta-3698A, mlta3698A, mlta 3698A
Latest Update: 2016-11-02
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Immunomodulator

Novel Mechanism: No

Modality: Antibody

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Pateclizumab

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Arthritis, Rheumatoid

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2010-021577-37

P2

Completed

Arthritis, Rheumatoid

2012-09-19

ALT4864g

P2

Completed

Arthritis, Rheumatoid

2012-07-01

Recent News Events

Date

Type

Title